Targeting glutamine metabolism enhances tumor specific immunity by inhibiting the generation of MDSCs and reprogramming tumor associated macrophages
Oh, M.-H.; Sun, I.-H.; Zhao, L.; Leone, R.; Sun, I.-M.; Xu, W.; Collins, S. L.; Tam, A. J.; Blosser, R. L.; Patel, C. H.; Englert, J.; Arwood, M. L.; Wen, J.; Chan-Li, Y.; Majer, P.; Rais, R.; Slusher, B. S.; Horton, M. R.; Powell, J. D.
Show abstract
Myeloid cells comprise a major component of the Tumor Microenvironment (TME) promoting tumor growth and immune evasion. By employing a novel small molecule inhibitor of glutamine metabolism not only were we able to inhibit tumor growth but we markedly inhibited the generation and recruitment of Myeloid Derived Suppressor Cells (MDSC). Targeting tumor glutamine metabolism led to a decrease in CSF-3 and hence recruitment of MDSC as well immunogenic cell death leading to an increase in inflammatory Tumor Associated Macrophages (TAMs). Alternatively, inhibiting glutamine metabolism of the MDSC themselves led to activation induced cell death and conversion of MDSC to inflammatory macrophages. Surprisingly, blocking glutamine metabolism also inhibited IDO expression of both the tumor and myeloid derived cells leading to a marked decrease in kynurenine levels. This in turn inhibited the development of metastasis and further enhanced anti-tumor immunity. Indeed, targeting glutamine metabolism rendered checkpoint blockade-resistant tumors susceptible to immunotherapy. Overall, our studies define an intimate interplay between the unique metabolism of tumors and the metabolism of suppressive immune cells.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Integrin αvβ8 on T cells is responsible for suppression of anti-tumor immunity in multiple syngeneic models and is a promising target for tumor immunotherapy 96%
- Neoantigen Cancer Vaccines and Different Immune Checkpoint Therapies Each Utilize Both Converging and Distinct Mechanisms that in Combination Enable Synergistic Therapeutic Efficacy 96%
- Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment 96%
Similar papers in this journal
- Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy 97%
- Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases 96%
- Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs 96%
Similar papers in this journal
Similar papers in this journal
- Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing Thymidine Phosphorylase 96%
- IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors 95%
- ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to γδ T cell immunotherapy 94%
Similar papers in this journal
- MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer 96%
- Combined PARP14 Inhibition and PD-1 Blockade Promotes Cytotoxic T Cell Quiescence and Modulates Macrophage Polarisation in Relapsed Melanoma 95%
- Tumor-Specific CD8+ T Cells from the Bone Marrow Resist Exhaustion and Exhibit Increased Persistence in Tumor-Bearing Hosts as Compared to Tumor Infiltrating Lymphocytes 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.